<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039156</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069358</org_study_id>
    <secondary_id>THERADEX-100389</secondary_id>
    <secondary_id>BAYER-100389</secondary_id>
    <secondary_id>SUNY-HSC-4553</secondary_id>
    <nct_id>NCT00039156</nct_id>
  </id_info>
  <brief_title>BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>An Open Phase II Multi-Center Trial of BAY 59-8862 in Patients With Aggressive Refractory Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theradex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who&#xD;
      have refractory non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the overall tumor response rate, including complete response (CR) and partial&#xD;
           response (PR) rate, in patients with aggressive refractory non-Hodgkin's lymphoma&#xD;
           treated with BAY 59-8862.&#xD;
&#xD;
        -  Determine the overall survival in patients treated with this drug.&#xD;
&#xD;
        -  Determine the time to progression in patients treated with this drug.&#xD;
&#xD;
        -  Determine the duration of response (CR and PR) in patients treated with this drug.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxicity profile of this drug in this patient&#xD;
           population.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this drug in selected patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, open-label study.&#xD;
&#xD;
      Patients receive BAY 59-8862 IV over 1 hour on day 1. Courses repeat every 3 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months until disease progression and then every 6 months&#xD;
      thereafter for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-140 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2002</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ortataxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed aggressive refractory non-Hodgkin's lymphoma (NHL) of one of&#xD;
             the following classifications, and for which chemotherapy is deemed appropriate:&#xD;
&#xD;
               -  Diffuse large B-cell lymphoma&#xD;
&#xD;
               -  Transformed NHL&#xD;
&#xD;
               -  Follicular large cell lymphoma&#xD;
&#xD;
               -  Peripheral T cell lymphoma&#xD;
&#xD;
               -  Anaplastic large cell lymphoma&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
               -  Unclassified aggressive histology&#xD;
&#xD;
               -  Immunoblastic lymphoma&#xD;
&#xD;
          -  Failed at least 1 prior therapy (primary resistant) OR&#xD;
&#xD;
          -  Previously achieved a remission and then progressed or relapsed within 6 months of&#xD;
             therapy&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lesion&#xD;
&#xD;
               -  Lesions within a previously irradiated field are not considered measurable&#xD;
&#xD;
          -  No relapse within 6 months after prior autologous bone marrow transplantation&#xD;
&#xD;
          -  No prior allogeneic bone marrow or stem cell transplantation or post-transplant&#xD;
             lymphoproliferative disorder&#xD;
&#xD;
          -  No parenchymal or meningeal CNS involvement unless the patient received prior&#xD;
             definitive therapy more than 6 months ago, has had a negative imaging study within the&#xD;
             past 4 weeks, and is clinically stable with respect to the tumor at study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Total bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST no greater than 2.0 times ULN (5.0 times ULN if hepatic involvement)&#xD;
&#xD;
          -  PT, INR, and PTT less than 1.5 times ULN&#xD;
&#xD;
          -  No chronic hepatitis B or C&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically evident congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No serious cardiac arrhythmias&#xD;
&#xD;
          -  No active coronary artery disease or ischemia&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior hypersensitivity to taxane compounds&#xD;
&#xD;
          -  No known or suspected allergy to the investigational study agent or any agent given in&#xD;
             association with this study&#xD;
&#xD;
          -  No other prior or concurrent malignancy except basal cell skin cancer or curatively&#xD;
             treated carcinoma in situ of the bladder or cervix (adequately cone biopsied)&#xD;
&#xD;
          -  No substance abuse or medical, psychological, or social conditions that would preclude&#xD;
             study participation&#xD;
&#xD;
          -  No active clinically serious infections&#xD;
&#xD;
          -  No other condition that is unstable or would preclude study participation&#xD;
&#xD;
          -  No grade 2 or greater pre-existing peripheral neuropathy&#xD;
&#xD;
          -  No history of seizure disorder&#xD;
&#xD;
               -  Prior seizures related to brain metastases allowed provided that the patient has&#xD;
                  been seizure-free for at least 2 months&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior anticancer immunotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior biologic response modifiers (e.g., filgrastim [G-CSF])&#xD;
&#xD;
          -  No concurrent anticancer immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic G-CSF&#xD;
&#xD;
          -  Concurrent G-CSF or other hematopoietic growth factors for acute toxicity (e.g.,&#xD;
             febrile neutropenia) allowed&#xD;
&#xD;
          -  Concurrent chronic epoetin alfa allowed provided no dose adjustment occurred within 2&#xD;
             months prior to study&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior anticancer chemotherapy&#xD;
&#xD;
          -  No more than 3 prior systemic chemotherapy regimens for metastatic NHL:&#xD;
&#xD;
               -  High-dose therapy for autologous hematopoietic stem cell transplantation (SCT) is&#xD;
                  considered 1 prior regimen&#xD;
&#xD;
               -  Salvage chemotherapy followed by autologous bone marrow transplant or peripheral&#xD;
                  SCT is considered 1 prior regimen&#xD;
&#xD;
               -  Antibody treatment is not considered 1 prior regimen&#xD;
&#xD;
          -  No prior taxanes or oxaliplatin&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Patients with prior parenchymal or meningeal CNS involvement:&#xD;
&#xD;
               -  No concurrent acute or tapered steroid therapy&#xD;
&#xD;
               -  Concurrent chronic steroid therapy allowed provided the dose is stable for 1&#xD;
                  month before and after screening radiographic studies&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  Concurrent palliative radiotherapy allowed provided:&#xD;
&#xD;
               -  No progressive disease&#xD;
&#xD;
               -  No more than 10% of bone marrow is irradiated&#xD;
&#xD;
               -  Radiation field does not encompass a target lesion&#xD;
&#xD;
          -  No other concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational therapy or approved anticancer therapy&#xD;
&#xD;
          -  No concurrent illicit drugs or other substances that would preclude study&#xD;
&#xD;
          -  Concurrent therapeutic anticoagulants (e.g., warfarin or heparin) allowed provided&#xD;
             there is no prior evidence of underlying abnormality with PT, INR, or PTT&#xD;
&#xD;
          -  Concurrent nonconventional therapies (e.g., herbs or acupuncture) or vitamin/mineral&#xD;
             supplements allowed provided that they do not interfere with study endpoints&#xD;
&#xD;
          -  Concurrent bisphosphonates for prophylaxis or bone metastases allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasim Ahmet Gucalp, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center - Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Clinical Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HemOnCare, P.C.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2004</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>IDN 5109</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

